Macro Finance
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
CNBC Business·September 21, 2026·1 min read
Eli Lilly CEO told CNBC that one-third of new GLP-1 pill patients are taking Foundayo, as the drugmaker ramps up production. Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space, according to the CEO's remarks.
Read at CNBC BusinessDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.